Molecular basis and clinical prospect of the miR-34 family for the treatment of gastric cancer
10.3760/cma.j.cn371439-20220927-00134
- VernacularTitle:miR-34家族用于胃癌治疗的分子基础及临床前景
- Author:
Wenjun JING
1
;
Wenwen ZHAO
;
Qingqing FENG
;
Wenfei ZHAO
;
Lili ZHAO
;
Xue ZHANG
;
Hongmei WEI
Author Information
1. 潍坊医学院临床医学院，潍坊 261053
- Keywords:
Gastric neoplasms;
MicroRNAs;
miR-34;
Epithelial-mesenchymal transition
- From:
Journal of International Oncology
2022;49(11):681-686
- CountryChina
- Language:Chinese
-
Abstract:
The miR-34 family plays an important role in gastric cancer, and the inactivation or reduced expression of the miR-34 family is detected in gastric cancer cell lines and gastric cancer tissues compared with normal gastric mucosa tissues, indicating it is associated with the occurrence and development of gastric cancer. Studies have shown that miR-34 plays a key role in inhibiting gastric cancer progression by regulating IGF2BP3, survivin, Bcl-2 and epithelial-mesenchymal transition-related pathway, indicating that miR-34 is an important target for gastric cancer treatment. In terms of clinical treatment, miR-34 has not only been proved to have radiochemotherapy sensitization, but also achieved good curative effect in tumor clinical trials. With the emergence of miR-34 vectors targeting gastric cancer, it is possible to use it for gastric cancer treatment. Deep understanding of the molecular basis and clinical efficacy of miR-34 for gastric cancer treatment can help to evaluate the potential of the miR-34 family as a new therapeutic target for gastric cancer.
